Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Details : Oral DehydraTECH-technology processed tirzepatide (GLP-1 + GIP agonist) is being investigated for diabetes mellitus and obesity.
Product Name : DehydraTECH-tirzepatide
Product Type : Peptide
Upfront Cash : Inapplicable
December 19, 2024
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
Details : Oral DehydraTECH-technology processed tirzepatide (GLP-1 + GIP agonist) is being investigated for diabetes mellitus and obesity.
Product Name : DehydraTECH-tirzepatide
Product Type : Peptide
Upfront Cash : Inapplicable
November 25, 2024
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
Details : Oral DehydraTECH-technology processed tirzepatide (GLP-1 + GIP agonist) is being investigated for diabetes mellitus and obesity.
Product Name : DehydraTECH-tirzepatide
Product Type : Peptide
Upfront Cash : Inapplicable
September 10, 2024
Lead Product(s) : Tirzepatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zucara Therapeutics Reports Positive Results from Phase 1b Trial of ZT-01
Details : Data from 18 subjects that completed all three hypoglycemic challenge (clamp) procedures demonstrated that nearly 90% of subjects had a meaningful increase in glucagon following ZT-01 compared to placebo.
Product Name : ZT-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2022
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Nova Mentis Life Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The psilocybin 1.5mg capsules are available for potential therapeutic use in non-ASD clinical trials, including but not limited to diabetes, heart disease, cancer, and post-traumatic stress disorder.
Product Name : NM-1001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Nova Mentis Life Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01
Details : Other study objectives include further evaluation of the safety and tolerability of ZT-01 and evaluation of symptoms and other hormones related to hypoglycemia. Topline results are expected in the first quarter of 2022.
Product Name : ZT-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2021
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01
Details : ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin, and restores glucagon secretion to prevent hypoglycemia.
Product Name : ZT-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2021
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01
Details : The study employs a single ascending dose (“SAD”) and multiple ascending dose (“MAD”) trial design and will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZT-01.
Product Name : ZT-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2020
Lead Product(s) : ZT-01
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable